Details About Generic Salt ::  Sufentan

Main Medicine Class:: Narcotic analgesic   

(sue-FEN-tuh-nill SIH-trate)

Sufenta, Sufentanil Citrate

Class: Narcotic analgesic

Drugs Class ::

 Action Relieves pain by stimulating opiate receptors in CNS; causes respiratory depression, peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of chemoreceptors that cause vomiting and increased bladder tone.

Indications for Drugs ::

 Indications Adjunct for surgical analgesia; induction of primary anesthesia for major surgical procedures requiring favorable myocardial or cerebral oxygen balance or when extended postoperative ventilation is anticipated; epidural analgesia with bupivacaine during labor and vaginal delivery.

Drug Dose ::

 Route/Dosage

General Surgery (with Nitrous Oxide/Oxygen)

ADULTS: IV 1 to 2 mcg/kg initially; 10 to 25 mcg prn for maintenance.

Major Surgical Procedures (with Nitrous Oxide/Oxygen)

ADULTS: IV 2 to 8 mcg/kg initially; 10 to 50 mcg prn for maintenance.

Major Cardiovascular Surgery/Neurosurgery (with 100% Oxygen)

ADULTS: IV 8 to 30 mcg/kg initially; 25 to 50 mcg prn for maintenance. CHILDREN < 12 YR: IV 10 to 25 mcg/kg initially; 25 to 50 mcg prn for maintenance.

Labor and Delivery

ADULTS: Epidural 10 to 15 mcg sufentanil mixed with 10 ml bupivacaine 0.125% with or without epinephrine. Can give total of 3 doses ³ 1 hr intervals until delivery.

Contraindication ::

 Contraindications Upper airway obstruction; acute asthma; diarrhea caused by poisoning or toxins.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy have been demonstrated in limited number of children < 2 yr undergoing cardiovascular surgery. Elderly or debilitated patients: May require dosage reduction. Special risk patients: Use drug with caution in patients with decreased respiratory reserve, head injury or increased intracranial pressure or hypoxia. Drug dependence: Has abuse potential. Hypoventilation: Naloxone and intubation equipment must be available in case hypoventilation occurs. Obese patients: If patient is > 20% above ideal weight, dose must be adjusted based on ideal body weight. Renal or hepatic impairment: Duration of action may be prolonged; dosage reduction may be required. Skeletal muscle rigidity: May cause skeletal muscle rigidity, particularly of the truncal muscles. The incidence and severity of muscle rigidity is usually dose-related.

Drug Side Effects ::

 Adverse Reactions

CV: Hypotension; orthostatic hypotension; hypertension; bradycardia; tachycardia; arrhythmias. CNS: Sedation. DERM: Pruritus. GI: Nausea; vomiting. RESP: Bronchospasm; depression of cough reflex; respiratory depression; postoperative respiratory depression; chest wall rigidity. OTHER: Chills; intraoperative muscle movement; tolerance.

Drug Mode of Action ::  

 Action Relieves pain by stimulating opiate receptors in CNS; causes respiratory depression, peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of chemoreceptors that cause vomiting and increased bladder tone.

Drug Interactions ::

 Interactions

Barbiturate anesthetics: May cause increased CNS and respiratory depression. Beta blockers: The incidence and degree of bradycardia and hypotension during induction of sufentanil may be greater in patients on chronic beta blocker therapy. Calcium channel blockers: The incidence and degree of bradycardia and hypotension during induction of sufentanil may be greater in patients on chronic calcium channel blocker therapy. Nitrous oxide: Nitrous oxide may cause cardiovascular depression with high-dose sufentanil.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess patient for head injury, pulmonary disease or decreased respiratory reserve.
• Maintain narcotic antagonist and resuscitative equipment at bedside.
• Monitor respiratory rate and BP closely during administration.
• Observe for evidence of effective induction of anesthesia.
• Monitor vital signs at frequent intervals postoperatively.

Drug Storage/Management ::

 Administration/Storage

• For direct IV administration, administer slowly over 1 to 2 min.
• Store at room temperature. Protect from light.
• Limit epidural or intrathecal administration of preservative free sufentanil to the lumbar area.

Drug Notes ::

 Patient/Family Education

• Inform patient that nausea, vomiting or constipation may occur and advise patient to notify physician should these symptoms become prominent.
• Advise patient to ask for assistance with ambulation.
• Instruct patient to report these symptoms to physician: shortness of breath or difficulty breathing.
• Caution patient to avoid sudden position changes to prevent orthostatic hypotension.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.